Key points are not available for this paper at this time.
Background: Rheumatoid arthritis endagers affected patients due to chronic inflammation in the synovial joints and increased cardiovascular morbidity. The latter is a result of ongoing inflammation as well as the potentially harmful effects of medications used to manage the disease, such as NSAIDs. Consequently, the assessment of cardiovascular risk (CVR) based on the 2018 ESC criteria may not accurately reflect the true CVR in RA individuals. Soluble IL-33 receptor (sST-2) has shown promise as a predictor of outcomes in acute kidney injury and other conditions. Objectives: In this study, we aimed to investigate the role of sST-2 in assessing disease activity and cardiovascular risk in rheumatoid arthritis. Methods: Observational, cross-sectional study including RA patients with or without DMARD therapy. RA disease activity and CVR were evaluated according to established criteria. Serum sST-2 was measured by ELISA. Results: A total of 129 patients were included in the study. Serum sST-2 did not correlate with, nor was it associated with any variable of RA disease activity (such as VAS, HFQ, DAS 28, or C-reactive protein). Aberrant sST-2 levels were, nonetheless, detected in various surrogate markers of increased cardiovascular risk (CVR), revealing numerous (n=17) significant findings in patients with rheumatoid arthritis (RA) (e.g. gender, age, distress, lack of regular exercise, familiy history of coronary artey disease, diabetes mellitus, framingham score and others.). Conclusion: Our findings reveal a novel role for sST-2 in predicting CVR in RA. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: None declared.
Patschan et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: